Multiple actions of somatostatin in neoplastic disease.
The role played by the neuropeptide somatostatin, also known as somatotropin release inhibitory factor (SRIF), in human cancer is not well understood. Recent investigations involving somatostatin receptors in normal and neoplastic human tissues suggest that the action is complex and involves both direct and indirect mechanisms. In this article, Jean-Claude Reubi and Jean Laissue describe the variety of biological mechanisms involved in neoplasia that are associated with somatostatin, and illustrate the therapeutic potential and present limitations of somatostatin analogues.
Reubi
J C
JC
Division of Cell Biology, University of Berne, Switzerland.
Laissue
J A
JA
D000818:Animals; D001158:Arteries / Q000187:drug effects; D002196:Capillaries / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D014680:Veins / Q000187:drug effects
D017481:Receptors, Somatostatin; D013004:Somatostatin